TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+5.19%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.8B
AUM Growth
+$2.8B
(+3.6%)
Cap. Flow
-$10.2M
Cap. Flow
% of AUM
-0.37%
Top 10 Holdings %
Top 10 Hldgs %
45.4%
Holding
164
New
19
Increased
21
Reduced
19
Closed
12
Top Buys
| 1 |
Gilead Sciences
GILD
|
$22M |
| 2 |
Thermo Fisher Scientific
TMO
|
$15.1M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$13M |
| 4 |
Johnson & Johnson
JNJ
|
$11M |
| 5 |
Edwards Lifesciences
EW
|
$10.6M |
Top Sells
| 1 |
iShares Biotechnology ETF
IBB
|
$23.6M |
| 2 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
$12.8M |
| 3 |
Biogen
BIIB
|
$12.6M |
| 4 |
Amgen
AMGN
|
$12M |
| 5 |
Puma Biotechnology
PBYI
|
$11.6M |
Sector Composition
| 1 | Healthcare | 93.03% |
| 2 | Real Estate | 2.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
51
Edwards Lifesciences
EW
$47.7B
| $10.6M | 0.38% |
+97,400
| New | +$10.6M |
|
52
CytomX Therapeutics
CTMX
$350M
| $9.63M | 0.34% |
530,092
| – | – |
|
|
DPLO
53
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $9.56M | 0.34% |
461,712
| – | – |
|
54
Merus
MRUS
$5.04B
| $9.52M | 0.34% |
479,150
| – | – |
|
55
Exelixis
EXEL
$9.95B
| $9.42M | 0.34% |
388,822
-162,825
| -30% | -$3.95M |
|
|
DOC
56
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $9.41M | 0.34% |
530,672
| – | – |
|
57
AbbVie
ABBV
$374B
| $9.29M | 0.33% |
104,513
+104,300
| +48,967% | +$9.27M |
|
|
NUVA
58
DELISTED
NuVasive, Inc.
NUVA
| $8.96M | 0.32% |
+161,576
| New | +$8.96M |
|
59
Sanofi
SNY
$122B
| $8.96M | 0.32% |
179,900
| – | – |
|
|
CLLS
60
Cellectis
CLLS
$260M
| $8.83M | 0.32% |
310,250
| – | – |
|
|
EPZM
61
DELISTED
Epizyme, Inc
EPZM
| $8.69M | 0.31% |
456,000
+175,000
| +62% | +$3.33M |
|
62
Elevance Health
ELV
$72.4B
| $8.53M | 0.3% |
+44,918
| New | +$8.53M |
|
63
Karyopharm Therapeutics
KPTI
$61.4M
| $8.31M | 0.3% |
756,679
| – | – |
|
64
Zimmer Biomet
ZBH
$20.8B
| $7.94M | 0.28% |
67,800
-34,500
| -34% | -$4.04M |
|
65
Ultragenyx Pharmaceutical
RARE
$3.04B
| $7.91M | 0.28% |
148,558
+21,250
| +17% | +$1.13M |
|
|
ENDP
66
DELISTED
Endo International plc
ENDP
| $7.83M | 0.28% |
914,548
| – | – |
|
|
PRAH
67
DELISTED
PRA Health Sciences, Inc.
PRAH
| $7.77M | 0.28% |
102,000
| – | – |
|
|
ADAP
68
Adaptimmune Therapeutics
ADAP
$13.9M
| $7.66M | 0.27% |
935,368
-531,000
| -36% | -$4.35M |
|
69
HCA Healthcare
HCA
$95.4B
| $7.58M | 0.27% |
95,232
| – | – |
|
|
TSRO
70
DELISTED
TESARO, Inc.
TSRO
| $7.44M | 0.27% |
+57,595
| New | +$7.44M |
|
|
ICPT
71
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $7.15M | 0.26% |
+123,200
| New | +$7.15M |
|
|
WMGI
72
DELISTED
Wright Medical Group Inc
WMGI
| $6.9M | 0.25% |
266,781
+52,000
| +24% | +$1.35M |
|
|
AVDL
73
Avadel Pharmaceuticals
AVDL
$1.42B
| $6.56M | 0.23% |
624,288
| – | – |
|
|
LTC
74
LTC Properties
LTC
$1.67B
| $6.4M | 0.23% |
136,212
| – | – |
|
|
ENTL
75
DELISTED
Entellus Medical, Inc. Common Stock
ENTL
| $6.3M | 0.23% |
341,471
| – | – |
|